Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. by Hout, J.M. van den et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/57497
 
 
 
Please be advised that this information was generated on 2018-07-08 and may be subject to
change.
Long-Term Intravenous Treatment of Pompe Disease With Recombinant
Human -Glucosidase From Milk
Johanna M.P. Van den Hout, MD, PhD*; Joep H.J. Kamphoven, MD*‡; Le´on P.F. Winkel, MD*;
Willem F.M. Arts, MD, PhD§; Johannes B.C. De Klerk, MD*; M. Christa B. Loonen, MD, PhD§;
Arnold G. Vulto, PharmD, PhD; Adri Cromme-Dijkhuis, MD, PhD¶;
Nynke Weisglas-Kuperus, MD, PhD#; Wim Hop, PhD**; Hans Van Hirtum, MSc‡;
Otto P. Van Diggelen, PhD‡; Marijke Boer, MSc‡; Marian A. Kroos, MSc‡;
Pieter A. Van Doorn, MD, PhD‡‡; Edwin Van der Voort, MD§§; Barbara Sibbles, MD, PhD;
Emiel J.J.M. Van Corven, PhD¶¶; Just P.J. Brakenhoff, PhD¶¶; Johan Van Hove, MD, PhD##;
Jan A.M. Smeitink, MD, PhD***; Gerard de Jong, MD, PhD‡‡‡; Arnold J.J. Reuser, PhD‡; and
Ans T. Van der Ploeg, MD, PhD*
ABSTRACT. Objective. Recent reports warn that the
worldwide cell culture capacity is insufficient to fulfill
the increasing demand for human protein drugs. Produc-
tion in milk of transgenic animals is an attractive alter-
native. Kilogram quantities of product per year can be
obtained at relatively low costs, even in small animals
such as rabbits. We tested the long-term safety and effi-
cacy of recombinant human -glucosidase (rhAGLU)
from rabbit milk for the treatment of the lysosomal stor-
age disorder Pompe disease. The disease occurs with an
estimated frequency of 1 in 40 000 and is designated as
orphan disease. The classic infantile form leads to death
at a median age of 6 to 8 months and is diagnosed by
absence of -glucosidase activity and presence of fully
deleterious mutations in the -glucosidase gene. Cardiac
hypertrophy is characteristically present. Loss of muscle
strength prevents infants from achieving developmental
milestones such as sitting, standing, and walking. Milder
forms of the disease are associated with less severe mu-
tations and partial deficiency of -glucosidase.
Methods. In the beginning of 1999, 4 critically ill pa-
tients with infantile Pompe disease (2.5–8 months of age)
were enrolled in a single-center open-label study and
treated intravenously with rhAGLU in a dose of 15 to 40
mg/kg/week.
Results. Genotypes of patients were consistent with
the most severe form of Pompe disease. Additional mo-
lecular analysis failed to detect processed forms of -glu-
cosidase (95, 76, and 70 kDa) in 3 of the 4 patients and
revealed only a trace amount of the 95-kDa biosynthetic
intermediate form in the fourth (patient 1). With the more
sensitive detection method, 35S-methionine incorpora-
tion, we could detect low-level synthesis of -glucosi-
dase in 3 of the 4 patients (patients 1, 2, and 4) with some
posttranslation modification from 110 kDa to 95 kDa in 1
of them (patient 1). One patient (patient 3) remained
totally deficient with both detection methods (negative
for cross-reactive immunologic material [CRIM nega-
tive]). The -glucosidase activity in skeletal muscle and
fibroblasts of all 4 patients was below the lower limit of
detection (<2% of normal). The rhAGLU was tolerated
well by the patients during >3 years of treatment. Anti-
rhAGLU immunoglobulin G titers initially increased
during the first 20 to 48 weeks of therapy but declined
thereafter. There was no consistent difference in anti-
body formation comparing CRIM-negative with CRIM-
positive patients. Muscle -glucosidase activity in-
creased from <2% to 10% to 20% of normal in all patients
during the first 12 weeks of treatment with 15 to 20
mg/kg/week. For optimizing the effect, the dose was in-
creased to 40 mg/kg/week. This resulted, 12 weeks later,
in normal -glucosidase activity levels, which were
maintained until the last measurement in week 72. Im-
portantly, all 4 patients, including the patient without
any endogenous -glucosidase (CRIM negative), re-
vealed mature 76- and 70-kDa forms of -glucosidase on
Western blot. Conversion of the 110-kDa precursor from
milk to mature 76/70-kDa -glucosidase provides evi-
dence that the enzyme is targeted to lysosomes, where
this proteolytic processing occurs. At baseline, patients
had severe glycogen storage in the quadriceps muscle as
revealed by strong periodic acid-Schiff–positive staining
and lacework patterns in hematoxylin and eosin–stained
tissue sections. The muscle pathology correlated at each
time point with severity of signs. Periodic acid-Schiff
intensity diminished and number of vacuoles increased
during the first 12 weeks of treatment. Twelve weeks
after dose elevation, we observed signs of muscle regen-
eration in 3 of the 4 patients. Obvious improvement of
muscular architecture was seen only in the patient who
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learned to walk. Clinical effects were significant. All
patients survived beyond the age of 4 years, whereas
untreated patients succumb at a median age of 6 to 8
months. The characteristic cardiac hypertrophy present at
start of treatment diminished significantly. The left ven-
tricular mass index decreased from 171 to 599 g/m2 (upper
limit of normal 86.6 g/m2 for infants from 0 to 1 year) to
70 to 160 g/m2 during 84 weeks of treatment. In addition,
we found a significant change of slope for the diastolic
thickness of the left ventricular posterior wall against
time at t  0 for each separate patient. Remarkably, the
younger patients (patients 1 and 3) showed no significant
respiratory problems during the first 2 years of life. One
of the younger patients recovered from a life-threatening
bronchiolitis at the age of 1 year without sequelae, de-
spite borderline oxygen saturations at inclusion. At the
age of 2, however, she became ventilator dependent after
surgical removal of an infected Port-A-Cath. She died at
the age of 4 years and 3 months suddenly after a short
period of intractable fever of >42°C, unstable blood pres-
sure, and coma. The respiratory course of patient 1 re-
mained uneventful. The 2 older patients, who both were
hypercapnic (partial pressure of carbon dioxide: 10.6 and
9.8 kPa; normal range: 4.5-6.8 kPa) at start of treatment,
became ventilator dependent before the first infusion
(patient 2) and after 10 weeks of therapy (patient 4).
Patient 4 was gradually weaned from the ventilator after
1 year of high-dose treatment and was eventually com-
pletely ventilator-free for 5 days, but this situation could
not be maintained. Currently, both patients are com-
pletely ventilator dependent. The most remarkable
progress in motor function was seen in the younger pa-
tients (patients 1 and 3). They achieved motor milestones
that are unmet in infantile Pompe disease. Patient 1
learned to crawl (12 months), walk (16 months), squat (18
months), and climb stairs (22 months), and patient 3
learned to sit unsupported. The Alberta Infant Motor
Scale score for patients 2, 3, and 4 remained far below p5.
Patient 1 followed the p5 of normal.
Conclusion. Our study shows that a safe and effective
medicine can be produced in the milk of mammals and
encourages additional development of enzyme replace-
ment therapy for the several forms of Pompe disease.
Restoration of skeletal muscle function and prevention
of pulmonary insufficiency require dosing in the range
of 20 to 40 mg/kg/week. The effect depends on residual
muscle function at the start of treatment. Early start of
treatment is required. Pediatrics 2004;113:e448–e457.
URL: http://www.pediatrics.org/cgi/content/full/113/
5/e448; transgenesis, enzyme therapy, lysosomal, muscular
dystrophy, glycogen storage disease.
ABBREVIATIONS. rhAGLU, recombinant human -glucosidase;
CHO, Chinese hamster ovary; PAS, periodic acid-Schiff; Ig, im-
munoglobulin; LVPWd, left ventricular posterior wall diastole;
LVMI, left ventricular mass index; AIMS, Alberta Infant Motor
Scale; BSIDII, Bayley Scales of Infant Development II; CRIM, cross-
reactive immunologic material; MDI, Mental Developmental
Index.
Production of therapeutic proteins in milk oftransgenic animals is a promising new technol-ogy in light of the rapidly expanding market
for protein drugs and the ever-increasing costs of
health care.1 As the transgenic protein concentration
in milk is very high, kilogram quantities of product
per year can be obtained at relatively low costs, even
in small animals such as rabbits.2
Since the first report in 1988 on -1-antitrypsin
production in sheep milk,3 a variety of transgenic
proteins have been produced. These range from
small unstable peptides (salmon calcitonin peptide4)
to large proteins with complex posttranslational
modifications (factor VIII5,6 and lactoferrin7). How-
ever, despite the great promises of this novel produc-
tion platform, there is not yet a single transgenic
medicine on the market. Three recombinant proteins
from milk are being tested in clinical trials: anti-
thrombin III from goats, -1-antitrypsin from sheep,
and -glucosidase from rabbits.8–10
We have focused on the production of recombi-
nant human -glucosidase (rhAGLU) for the treat-
ment of Pompe disease, an autosomal recessive mus-
cle disorder. The classic infantile form of the disease
leads to death at a median age of 6 to 8 months11 and
is diagnosed by absence of -glucosidase activity
and presence of fully deleterious mutations in the
-glucosidase gene.12 Cardiac hypertrophy is charac-
teristically present.11 Loss of muscle strength pre-
vents infants from achieving developmental mile-
stones such as sitting, standing, and walking.11–13
Milder forms of the disease caused by less severe
mutations and partial deficiency of -glucosidase are
also known. Pompe disease is a lysosomal glycogen
storage disorder with an estimated frequency of
1:40 000 births14,15 and is designated an orphan dis-
ease.
We have successfully explored the feasibility of
enzyme therapy for Pompe disease in preclinical
studies.16–19 The principle of treatment is based on
the capacity of lysosomes to engulf exogenous pro-
teins via endocytosis.20 After cloning the human
-glucosidase gene, we have focused on production
of the enzyme in Chinese hamster ovary (CHO) cells
and milk of transgenic animals.18,19,21–25 The high
yield of 2 g/L and the short reproduction time of
rabbits has led to the pharmaceutical production of
rhAGLU in milk of transgenic rabbits. The product’s
safety and efficacy were tested in phase I and phase
II clinical studies.10 Here we report how 4 patients
with infantile Pompe disease responded in a fol-
low-up study to 3 years of intravenous treatment.
METHODS
Enzyme Purification and Characterization
A line of transgenic rabbits producing rhAGLU was obtained.19
Rabbit milk was collected and stored at 20°C until use. An
-glucosidase containing whey fraction was prepared from
skimmed milk by tangential flow filtration using a Biomax 1000
membrane cassette (Millipore, Bedford, MA) and subsequently
concentrated by ultrafiltration using a Biomax 30 membrane (Mil-
lipore). After a virus inactivation step with Tween-80 in 1% and
tri-n-butylphosphate in 0.3% concentration for 6 hours at 25°C, the
-glucosidase was subsequently captured by Q Sepharose Fast
Flow chromatography (Amersham Pharmacia Biotech, Uppsala,
Sweden). After intermediate purification on a Phenyl Sepharose
HP column (Amersham Pharmacia Biotech), -glucosidase was
polished by Source Phenyl 15 chromatography (Amersham Phar-
macia Biotech). After a second viral removal step by nanofiltra-
tion, purified -glucosidase was concentrated by ultrafiltration
(Biomax 30 membrane) and sterilized by microfiltration (0.2-m
dead-end filter). The enzyme has a specific activity of250 mol/
mg/hour for 4-methylumbelliferyl--D-glucopyranoside and is
95% pure. Toxicity studies were performed in mice, rats, and
dogs in doses up to 100 mg/kg. A phase I study was completed
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successfully in humans. All information is contained in the Inves-
tigator’s Brochures.
Biochemical-Genetic Studies
Skin fibroblasts and muscle specimens were homogenized in
water, and the 2000  g supernatants were used to determine
-glucosidase activity, glycogen content, and protein concentra-
tion.19,26 Mutation analysis was performed on genomic DNA and
cDNA, as described previously.27 The functional effects of muta-
tions were studied by assay of -glucosidase synthesis and cata-
lytic activity in transiently transfected COS cells.27,28
Study Design
The study was a single-center, open-label, phase II study ap-
proved by the institutional review board. Written informed con-
sent was obtained from the parents of all patients. The objective of
the study was to evaluate the safety and efficacy of rhAGLU.
Inclusion Criteria
Patients qualified for inclusion when they had symptoms char-
acteristic of the infantile form of Pompe disease, including a
hypertrophic cardiomyopathy. The upper age limit was 10
months. Confirmation of the diagnosis was required by an open
biopsy from the quadriceps muscle, revealing a virtual absence of
-glucosidase activity and the presence of lysosomal glycogen
storage.
Clinical Studies
RhAGLU was administered intravenously as a 1- to 2-mg/mL
solution in saline with 5% glucose and 0.1% human serum albu-
min, in single starting doses of 20 mg/kg weekly for patients 6.5
kg and 15 mg/kg for patients 6.5 kg. After 14 to 23 weeks of
treatment, the dose was increased to 40 mg/kg weekly for all
infants. During infusions, heart rate, temperature, transcutaneous
oxygen saturation, and blood pressure were recorded continu-
ously.
Before the start of rhAGLU treatment, there was a period of up
to 2 weeks in which baseline assessments were performed. There-
after, patients were assessed at regular intervals. Muscle biopsies
were taken from the quadriceps muscle via an open muscle biopsy
1 day after rhAGLU infusion. Tissue specimens for measurement
of -glucosidase were frozen immediately in liquid nitrogen and
stored at 80°C until use. For histology purposes, tissue speci-
mens were fixed in 4% glutaraldehyde and embedded in glycol-
methacrylate. Tissue sections (4 m) were stained with periodic
acid-Schiff (PAS). Slides that were prepared at different time
points were stained in 1 session.
Immunoglobulin E (IgE) and IgG antibody titers were detected
using a standard enzyme-linked immunosorbent assay in which
the plates were coated with antigen (1 g/mL) and the samples
were diluted 5-fold for IgE and 100-fold for IgG. Samples from
healthy volunteers served as negative controls.
Left ventricular dimensions were determined by M-mode echo-
cardiography, in compliance with the guidelines of the American
Society of Echocardiography, using a Hewlett Packard Sonos
5500.29 The diastolic thickness of the left ventricular posterior wall
(LVPWd) and the calculated left ventricular mass index (LVMI)
were used as measures of hypertrophic cardiomyopathy.30 Psy-
chomotor development was assessed using the Alberta Infant
Motor Scale (AIMS),31 the Bayley Scales of Infant Development II
(BSIDII),32 and regular standardized neurologic examinations.
RESULTS
RhAGLU From Rabbit Milk
To achieve high-level expression of rhAGLU in the
mammary gland, we placed the entire -glucosidase
gene under control of the bovine S1-casein gene
promoter. The gene construct was injected into fer-
tilized rabbit oocytes, and these were implanted in
foster mothers. Thus, we obtained a line of trans-
genic rabbits with high-level expression of rhAGLU
during lactation.18 The production line yields on av-
erage of 2 g of crude rhAGLU per liter of milk during
the first 3 weeks of lactation. The molecular mass of
-glucosidase from milk is 110 kDa (Fig 1A), similar
to the mass of the acid -glucosidase precursor pro-
duced in genetically engineered CHO cells, and both
enzyme species contain uncleaved N- and C-termi-
nal pro-peptides.18,24,33
Clinical Condition and Molecular Delineation of
Patients
RhAGLU from rabbit milk was tested for its safety
and therapeutic efficacy in an open-label study in 4
patients who had the most severe infantile form of
Pompe disease and fulfilled the inclusion criteria as
described in the Methods section. The clinical status
of the 4 patients at baseline is summarized in Table 1.
To sustain the diagnosis of classic infantile Pompe
disease, the patients were characterized with regard
to the degree of acid -glucosidase deficiency, the
pattern of -glucosidase synthesis, and the type of
-glucosidase gene mutations. The -glucosidase ac-
tivity in skeletal muscle and fibroblasts of all 4 pa-
tients was below the lower limit of detection (2% of
normal; Table 2). The 95-, 76-, and 70-kDa biosyn-
thetic forms of -glucosidase were missing in 3 of the
4 patients, when investigated by Western blot anal-
ysis (Fig 2A). A trace amount of the naturally occur-
ring 95-kDa biosynthetic intermediate was seen in
cultured fibroblasts from the fourth patient (patient
1). When we used a more sensitive detection method,
35S-methionine incorporation, we could detect low-
level synthesis of -glucosidase in 3 of the 4 patients
(patients 1, 2, and 4) and some posttranslation mod-
ification from 110 kDa to 95 kDa in 1 of them (patient
1; Fig 2B). Patient 3 remained totally deficient with
both detection methods (negative for cross-reactive
immunologic material [CRIM negative]). As a third
mode of molecular delineation, we analyzed the ge-
notype of the patients (Table 2). The CRIM-negative
patient (patient 3) turned out to be homozygous for
T525, a mutation known to lead to unstable mRNA,
frame shift, and absence of CRIM.34 Both of her
parents are carriers of this mutation. Each of the
other 3 patients has at least 1 -glucosidase allele
with a mutation permitting low-level synthesis of the
Fig. 1. Characterization of rhAGLU from rabbit milk. A, Sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE;
8%) analysis under reducing conditions. The gel was loaded with
50 g of protein per lane and stained with Coomassie brilliant
blue. The 110-kDa precursor from rabbit milk (M) is compared
with the 76- and 70-kDa mature forms of acid -glucosidase from
human placenta. B, Western blot analysis of -glucosidase derived
from muscle of patient 3 (P3) before (t  0) and after (t  3)
treatment. -Glucosidase from fibroblasts of a healthy individual
is used to mark and identify the various molecular forms.
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110-kDa precursor when overexpressed in COS cells
(Fig 2C). In 2 cases (patients 2 and 4), the precursor is
degraded, but in 1 (patient 1), the Arg600His substi-
tution is compatible with the formation of some 95-
kDa intermediate. Importantly, none of the mutant
alleles generates catalytically active -glucosidase,
despite overexpression. Thus, the genotype of all
patients enrolled in the study is consistent with the
classic infantile phenotype of Pompe disease.
RhAGLU Tolerability
RhAGLU was administered intravenously, in an
initial dose of 15 to 20 mg/kg/week. The dose was
later increased to 40 mg/kg/week. The duration of
the infusions ranged from 4 to 8 hours. Infusion-
associated reactions were observed in the initial
phase of treatment (starting at weeks 5–7) as re-
ported previously. They comprised fever, malaise,
erythematous rash, sweating, hypoxia, flushing, and
Fig. 2. Molecular forms of -glucosidase. A, Western blot analysis. -Glucosidase was immunoprecipitated from fibroblast lysates with
rabbit anti-human -glucosidase antibodies and subjected to SDS-PAGE. -Glucosidase on the Western blots was visualized with mouse
anti-human -glucosidase antibodies and chemoluminescence. The numbers above the lanes correspond to the patient number. N are cells
from a healthy individual. Each lane shows the relative amount and molecular mass of the -glucosidase species present in an aliquot of
lysate containing 1 mg of total cellular protein. B, Synthesis and posttranslational modification of -glucosidase. Fibroblasts were
incubated for 8 hours in medium containing 35S-methionine and then harvested. -Glucosidase was immunoprecipitated from cell lysates
with rabbit anti-human -glucosidase antibodies and subjected to SDS-PAGE. The autoradiogram shows the processing forms of
-glucosidase. The numbers above the lanes correspond to the patient number. N are cells from a healthy individual. Equal numbers of
cells were labeled per lane. C, Functional effects of novel mutations. Mutations were introduced in wild-type cDNA by site-directed
mutagenesis and transiently expressed in COS cells. -Glucosidase was immunoprecipitated from cells and media at 72 hours after
transfection and analyzed by Western blotting, as described above. The numbers above the lanes correspond to the patient number. N is
the wild-type construct. Equal numbers of cells and equal volumes of media were used per lane.
TABLE 1. Clinical Characteristics of Patients at Baseline
Patient Gender/Age at Start
of Treatment
Clinical Appearance
1 M/3 mo Cardiac hypertrophy, head lag, slipping through, axial hypotonia
2 F/7 mo Cardiac hypertrophy, heart failure, hypercapnia, oxygen need,
head lag, slipping through, axial hypotonia, poor head balance,
paresis arms, paralysis legs, nasogastric tube feeding
3 F/2.5 mo Cardiac hypertrophy, heart failure, tachypnea, borderline oxygen
saturations, extreme perspiration, head lag, slipping through,
axial hypotonia, poor head balance, nasogastric tube feeding
4 F/8 mo Cardiac hypertrophy, heart failure, oxygen need, atelectasis left
lung, head lag, slipping through, axial hypotonia, poor head
balance, paresis arms, paralysis legs, nasogastric tube feeding,
growth retardation, intractable fever
TABLE 2. Biochemical-Genetic Delineation of Patients
Patient -Glucosidase*
Activity
Genotype Amino Acid
Substitution
1 0.6 G1799A/del exon 18 R600H/del55AA
2 0.5 A1115T/delT525 H372L/†
3 0.1 delT525/delT525 /†
4 0.7 G1913T/silent G638V/‡
Control 40–160
* The activities are expressed as nmol 4-methylumbelliferon formed per hour per milligram of cellular
protein.
† The delT525 is not expressed at the protein level.
‡ The G1913T mutation was heterozygous in genomic DNA and homozygous in cDNA obtained by
reverse transcriptase–polymerase chain reaction, indicating that only the G1913T allele is expressed.
http://www.pediatrics.org/cgi/content/full/113/5/e448 e451
tachycardia.10 Corticosteroids and antihistamines
were given in this period but did not have a signif-
icant effect and were discontinued. The reactions
disappeared and did not occur when low infusion
rates were applied (2–10 mL/hour) for the first 2
hours. They did not recur when the dose was dou-
bled. In the later phase of treatment, infusion reac-
tions occurred only sporadically in the form of low-
grade fever and rash. They were transient and mild.
None of the patients receives at present antihista-
mines or corticosteroids. The infusions are easily
manageable on an outpatient basis. One patient re-
ceives the infusions at home.
The IgE titer did not rise above background levels
during the study. Anti-rhAGLU IgG titers increased
to levels between 5 and 13 times baseline values
during the first 20 to 48 weeks and declined to 1 and
8 times baseline values during the following infu-
sions. IgG titers against rabbit whey also increased
(4–12 times baseline values) during the first 24 weeks
and then stabilized between 3 and 9 times baseline
values. There was no consistent difference in anti-
body formation comparing the CRIM-negative with
the CRIM-positive patients. Notably, we measured
the highest IgG titer in a 34-year-old patient with
10% to 20% of normal CRIM who received the same
enzyme preparation.
-Glucosidase Activity in Tissues
During the first 12 weeks of treatment, muscle
-glucosidase activity increased from 2% to 10% to
20% of normal in all patients (Table 3). To optimize
the therapeutic effect, we increased the rhAGLU
dose in all infants to 40 mg/kg, and this resulted, 12
weeks later, in normal -glucosidase activity levels.
These were maintained until the last measurement in
week 72. Importantly, all 4 patients, including the
patient without any endogenous -glucosidase
(CRIM negative), revealed mature 76- and 70-kDa
forms of -glucosidase on Western blot after treat-
ment with the 110-kDa (precursor) rhAGLU (Fig 1).
As the final steps of enzyme maturation occur in
lysosomes, this observation provides evidence that
rhAGLU reaches its target.
Muscle Morphology
At baseline, all patients had severe glycogen stor-
age in the quadriceps muscle as revealed by strong
PAS-positive staining and lacework patterns in he-
matoxylin and eosin–stained tissue sections. The 2
older patients had more severely affected muscle at
inclusion than the 2 younger ones. The muscle pa-
thology correlated at each time point with the sever-
ity of signs. After 12 weeks of treatment with 15 or 20
mg/kg rhAGLU, the PAS intensity had diminished,
whereas the number of vacuoles had increased.
Twelve weeks after dose elevation, we observed
signs of muscle regeneration in 3 of the 4 patients. An
obvious improvement of muscular architecture was
seen only in the patient who learned to walk (Fig
3A). A detailed account of the morphologic changes
in muscle is given.35 The glycogen concentration in
muscle stabilized in patients 2, 3, and 4 and de-
creased in patient 1 during the course of treatment
(Table 3).
Cardiac Morphology and Function
All 4 patients had the characteristic cardiac hyper-
trophy at start of treatment, with an LVMI exceeding
170 g/m2 (normal value P97.5 86.6 g/m2 for infants
from 0 to 1 year of age36). During 84 weeks of treat-
ment, the LVMI decreased from 171, 203, 308, and
599 g/m2 at baseline to 70, 160, 104, and 115 g/m2 for
patients 1, 2, 3, and 4, respectively. The decrease of
the LVMI along time appeared linear (r.86,.91,
.89, and .80 for the 4 respective patients; all P 
.01). The LVPWd was increased before start of rhA-
GLU treatment. We found a significant change of
slope for LVPWd against time at t  0 for each
separate patient (P  .01; Fig 3B). The decrease in
LVPWd after the start of treatment leveled out in 2
patients (patients 3 and 4) when the P95 of normal
was approached, as evidenced by a second signifi-
cant change of slope using the “broken stick” method
(P  .05). The systolic function normalized and the
diastolic function improved in all patients.
Respiratory Condition
During the first 2 years of life, the 2 younger
patients (patients 1 and 3) remarkably showed no
TABLE 3. Uptake of -Glucosidase in Muscle and Correction of Glycogen Storage
Patient t  0 t  1 t  2 t  3
-Glucosidase activity*
1 0.2/0.4 4.9/3.7 27.4/29.3 27.1/25.8
2 0.3/0.3 2.7/3.1 8.0/9.5 28.9/12.1
3 0.2/0.7 2.1/3.8 13.0/7.4 8.2/8.9
4 0.4/0.2 2.7/1.8 16.2/11.3 5.8/4.4
Control 8–40
Glycogen concentration*
1 747/1022 755/1351 892/1440 86/503
2 2810/2543 3270/3199 2450/3190 2460/3020
3 1650/1397 2330/1847 2020/2440 2300/2550
4 3690/2720 4630/3700 3060/2720 2130/2310
Control 30–180
* Multiple measurements of -glucosidase activity (nmol/mg/hour) and glycogen concentration
(g/mg) in muscle at baseline (t  0) and after 12 weeks of treatment with 15 to 20 mg/kg (t  1), 12
more weeks of treatment with 40 mg/kg (t  2), and 72 more weeks of treatment (t  3). Values at
each time point were obtained from 2 different pieces of muscle.
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significant respiratory problems. Patient 3 recovered
from a life-threatening bronchiolitis at the age of 1
year without sequelae, despite borderline oxygen
saturation at inclusion. At the age of 2, she became
ventilator dependent after surgical removal of an
infected Port-A-Cath. The respiratory course of pa-
tient 1, now 4 years of age, remained uneventful.
Patients 2 and 4, who were older and more severely
affected at inclusion, had a marginal respiratory con-
dition from the start of treatment, and both required
oxygen. Patient 2 (partial pressure of carbon dioxide:
10.6 kPa equivalent to 80 mm Hg at start; normal
range: 4.5–6.8 kPa) became ventilator dependent be-
fore the first rhAGLU infusion and remained fully
ventilated. Patient 4 (partial pressure of carbon diox-
ide: 9.8 kPa equivalent to 75 mm Hg at start) became
ventilator dependent during a bout of pneumonia
after 10 weeks of low-dose treatment. She could
gradually be weaned from the ventilator after 1 year
of high-dose treatment and was eventually com-
pletely ventilator-free for 5 days, but this situation
could not be maintained. At the age of 4, her venti-
lator needs are 24 hours per day.
Motor Development
The most remarkable progress in motor develop-
ment was seen in the younger patients (patients 1
and 3; Fig 4). Patient 1 learned to crawl (12 months),
walk (16 months), squat (18 months), and climb stairs
(22 months). Patient 3 learned to sit unsupported (Fig
4), and her condition further improved until the age
of 2, when she became ventilator dependent. At the
age of 4 years and 3 months, she died suddenly after
a short period of intractable fever of 42°C, unstable
blood pressure, and coma. At baseline, the older
patients (patients 2 and 4) could hardly lift their arms
Fig. 3. Correction of muscle pathology and improvement of cardiac and skeletal muscle function. A, Longitudinal sections of a muscle
biopsy from patient 1 at baseline (left) and 72 weeks of treatment (right). Sections are stained with PAS to visualize lysosomal glycogen.
B, Changes in LVPWd during treatment for patients 1 to 4. Piece-wise linear regression (“broken-stick” method) is used to illustrate the
statistically significant change in slope after start of treatment.
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while in a supine position, and their legs lay immo-
bile on the surface. During treatment, the muscle
function of the arms improved significantly. Patient
2, however, lost her regained muscle strength after a
series of airway infections. In her case, restoration of
function seems to be a difficult process. Patient 4
maintained the strength in her arms. When she was
24 months of age, she could roll over onto her side
and play for longer periods while seated in a wheel
chair. Her condition has not improved since then.
Over time, there was a mild decline in the active
elevation of the upper arms from 90 degrees to 45
degrees. The AIMS score for patients 2, 3, and 4
remained far below the p5. Patient 1 followed the p5
of normal (Fig 5). For patient 1, the psychomotor
development on the BSIDII, based on raw score
equivalents, progressed from 2 to 37 months’ devel-
opmental ages at chronological ages of 3 to 37
months. The Psychomotor Developmental Index
progressed from 79 to 97. In patients 2, 3, and 4, the
Psychomotor Developmental Index was 50, and a
motor developmental age could not be calculated.
Mental Development
As rhAGLU is unlikely to pass the blood-brain
barrier, we had concerns about long-term mental
development and neurologic performance. Neuro-
logic examinations performed from the start of treat-
ment at preset time points showed no signs of central
nervous system involvement so far. As an unex-
pected finding, we measured an elevated response
threshold of brainstem auditory evoked potentials in
all patients at inclusion. This did not change during
treatment.
For patient 1, the mental development on the BSID
II, based on raw score equivalents, progressed from 3
to 31 months’ developmental ages at chronological
ages of 3 to 37 months. The Mental Developmental
Index (MDI) was 101 and 79 at 3 months and 37
months, respectively. The BSIDII was inadequate to
Fig. 4. Motor development. A, Patient 1 stands on 1 leg at 4.5
years of age. B, Patient 3 sits without support at the age of 19
months.
Fig. 5. The AIMS scores of the patients during enzyme replace-
ment therapy. The upper age limit of the test is 18 months.
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test the mental development of patient 2 because of
her severe hypotonia. For patient 3, the mental de-
velopment progressed from 2 to 18 months at chro-
nological ages of 3 to 22 months. The MDI was 81
and 72, respectively. The mental development of pa-
tient 4 progressed from 5 to 27 months at chronolog-
ical ages of 8 to 37 months. The MDI of patient 4 was
76 and 67, respectively.
In practice, the BSIDII scores are not a true reflec-
tion of mental development. Items were missed
through motor handicaps and hearing problems
rather than through mental delay. All patients were
interested in their environment, interacted with their
parents, and were able to attend school.
Survival
Three of the 4 patients are alive. All 4 patients
reached the age of 4 years, whereas the life expect-
ancy of untreated patients with the classic infantile
form of Pompe disease is typically 1 year.10–13
DISCUSSION
Our study demonstrates that a safe and effective
medicine for intravenous treatment of human dis-
ease can be produced in the milk of transgenic ani-
mals, in this case rhAGLU from rabbit milk for pa-
tients with Pompe disease. The safety of the product
is proved by the fact that 700 infusions were well
tolerated by critically ill patients. The efficacy of the
therapy is evident from several observations. First,
all 4 patients have reached the age of 4 years, and 1
patient remained ventilator-free, whereas infants
with classic infantile Pompe disease typically suc-
cumb before they are 1 year of age.10–13 Second, the
cardiac hypertrophy diminished and cardiac func-
tion improved, whereas cardiac failure is a major
cause of death in infantile Pompe disease. Third,
patients gained muscle strength, whereas there nor-
mally is a progressive loss of muscle function. Two
patients achieved developmental milestones that are
unmet by untreated patients. Notably, the motor
score on the BSIDII of 1 patient normalized at the age
of 2 years.
The efficacy of treatment is further supported by
biochemical findings. Correction of -glucosidase
deficiency occurred in skeletal muscle of all 4 pa-
tients. After 3 months of single weekly doses of 15 to
20 mg/kg, the correction was partial. A 100% correc-
tion was achieved after 3 additional months on a
weekly dose of 40 mg/kg. Conversion of the 110-kDa
precursor from milk to mature 76/70-kDa -glucosi-
dase provides evidence that the enzyme is targeted
to lysosomes, where this proteolytic processing oc-
curs.37 Moreover, we observed a decrease of the
PAS-staining intensity and the appearance of empty
vacuoles in the quadriceps muscle of all patients,
suggestive of an effect on the lysosomal glycogen
pool. In the best performing patient, this resulted in
greatly improved muscle morphology and glycogen
content.35
It is evident that the 4 patients respond differently
to the treatment, and we have tried to find an expla-
nation. All patients seemed to have molecular-ge-
netic defects and clinical characteristics consistent
with classic infantile Pompe disease.11–13 Notably,
the best performing patient had the most severe
hearing deficit (50–80 dB). This makes it unlikely
that the difference in response is explained by inclu-
sion of patients with milder nonclassic infantile phe-
notypes.
We find it equally unlikely that an inhibitory im-
mune response, as described in a study by
Amalfitano et al38 with -glucosidase from CHO
cells, explains the difference in efficacy. That study
claimed that neutralizing antibodies caused the loss
of treatment benefit at the age of 8 months in 2
CRIM-negative patients. This counter-effect did not
occur in our study. On the contrary, our truly CRIM-
negative patient was the second best responder. En-
zyme therapy studies for Gaucher disease, Fabry
disease, and mucopolysaccharidosis type I do not
indicate either that a CRIM-negative status per se or
an antibody formation interferes with the efficacy of
enzyme replacement therapy.39–43
In our view, the degree of impairment of skeletal
muscle function and the age of the patient at start of
treatment play the decisive roles in outcome. The 2
patients, included at 2.5 and 3 months of age, had
milder symptoms at inclusion and responded clearly
better than the 7- and 8-month-old patients who
were in an end stage of the disease at the time of
inclusion. The patient who had the best muscle func-
tion at start of treatment learned to walk. This may
indicate that active muscle movement is required to
correct the lysosomal glycogen storage and restore
the muscle morphology.35
Despite the significant effects of our therapy, we
warn that patients with infantile Pompe disease are
at risk of developing residual disease with contrac-
tures, scoliosis, or respiratory insufficiency if treat-
ment is started too late or with a too low a dose. The
therapeutic window is small. We may have lost pre-
cious time by treating the patients for 3 to 6 months
with a suboptimal dose.
The results of our study are encouraging for the
additional exploration of enzyme replacement ther-
apy. This is true for infants but even more so for
patients with milder forms of Pompe disease. The
therapeutic window is larger as we experienced in
our pilot study with 3 patients aged 12 to 33 years.
One of them, who was wheelchair-bound for 4 years,
started to walk again after 2 years of treatment with
rhAGLU, 20 mg/kg/week.44
The effective dose of rhAGLU is high compared
with the 1-mg/kg dose of glucocerebrosidase used
for the treatment of type 1 Gaucher disease and the
0.2- to 1-mg/kg dose of -galactosidase used for
treatment of Fabry disease.39–41,43,45 These differ-
ences are explainable by the different target tissues.
In Pompe disease, the target tissue (skeletal muscle)
is shielded from the enzyme by the capillary endo-
thelium and the interstitial tissue. In contrast, the
targets in Gaucher disease (liver and spleen macro-
phages) and Fabry disease (endothelial cells) are di-
rectly exposed to circulating enzyme. Notably, in
Fabry disease, 3 mg/kg -galactosidase is sufficient
to reach the endocardium but insufficient to reach
the cardiomyocytes.40 The higher dose required to
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correct enzyme activity in skeletal muscle is sup-
ported by studies in animal models and was demon-
strated for various enzyme species among which was
rhAGLU from both transgenic mammals and genet-
ically engineered CHO cells.19,33,46,47
CONCLUSION
The results of our study demonstrate both the
safety and the efficacy of enzyme replacement ther-
apy in Pompe disease as well as the feasibility of
producing medicines in the milk of transgenic ani-
mals. This novel production platform can potentially
reduce the costs of therapeutics, but scale-up persists
as a major challenge in the rhAGLU production pro-
cess. The currently used transgenic rabbit production
line supplies 10 g of rhAGLU per animal per year.
At a dose of 10 to 40 mg/kg per patient per week, the
production of rhAGLU in rabbit milk is feasible in
the initial phase of product development but falls
short of supplying patients with Pompe disease
worldwide. The more conventional production sys-
tem in genetically modified CHO cells can be used as
an alternative but also has a capacity limitation.1
Thus, timely investments need to be made in the
development of alternative production platforms.
Our studies show that production in milk of sheep,
goat, or cow is the option of choice.
ACKNOWLEDGMENTS
The study was sponsored by Pharming-Genzyme LLC and
financed in part by a grant from the Sophia Foundation for Med-
ical Research (J.H.J.K. and L.P.F.W.).
We thank the patients and parents for participating in this
study and all who have given their support: F. Bel, M. Bruning, M.
Etzi, A. Franken, L. van der Giessen, J. Huijmans, J.T. Janiak, R.M.
Koppenol, L.J.F. Ko¨nigs, G. Kreek, P. Merkus, M. Moens, M.
Plugge, J. Ponsen, L. Schuddink, L.-A. Severijnen, L. Vendrig, H.
Versprille, M. de Visser, T. de Vries Lentsch, G.A. van Zanten, the
staff of the Pharmacy, the Clinical Genetic and Neurophysiologi-
cal laboratory, H. Galjaard, and H.A. Bu¨ller.
REFERENCES
1. Mynahan R, Anderson R. The protein production challenge. In vivo. Bus
Med Rep. 2001;72
2. Janne J, Alhonen L, Hyttinen JM, Peura T, Tolvanen M, Korhonen VP.
Transgenic bioreactors. Biotechnol Annu Rev. 1998;4:55–74
3. Simons JP, Wilmut I, Clark AJ, Archibald AL, Bishof JO, Lathe R. Gene
transfer into sheep. Biotechnology. 1988;6:113–120
4. McKee C, Gibson A, Dalrymple M, Emslie L, Garner I, Cottingham I.
Production of biologically active salmon calcitonin in the milk of trans-
genic rabbits. Nat Biotechnol. 1998;16:647–651
5. Niemann H, Halter R, Carnwath JW, Herrmann D, Lemme E, Paul D.
Expression of human blood clotting factor VIII in the mammary gland
of transgenic sheep. Transgenic Res. 1999;8:237–247
6. Paleyanda RK, Velander WH, Lee TK, et al. Transgenic pigs produce
functional human factor VIII in milk. Nat Biotechnol. 1997;15:971–975
7. Van Berkel PH, Welling MM, Geerts M, et al. Large scale production of
recombinant human lactoferrin in the milk of transgenic cows. Nat
Biotechnol. 2002;20:484–487
8. Lu W, Mant T, Levy JH, Bailey JM. Pharmacokinetics of recombinant
transgenic antithrombin in volunteers. Anesth Analg. 2000;90:531–534
9. Carver AS, Dalrymple MA, Wright G, et al. Transgenic livestock as
bioreactors: stable expression of human alpha-1-antitrypsin by a flock of
sheep. Biotechnology. 1993;11:1263–1270
10. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis
A, Van der Ploeg AT. Recombinant human alpha-glucosidase from
rabbit milk in Pompe patients. Lancet. 2000;356:397–398
11. van den Hout JMP, Hop W, van Diggelen OP, et al. The natural course
of infantile Pompe’s disease: 20 original cases compared with 133 cases
from the literature. Pediatrics. 2003;112:332–340
12. Hirschhorn R, Reuser AJJ. Glycogen storage disease type II: acid alpha-
glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet A, Sly
WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease.
8th ed. New York, NY: McGraw-Hill; 2001:3389–3420
13. Slonim AE, Bulone L, Ritz S, Goldberg T, Chen A, Martiniuk F. Identi-
fication of two subtypes of infantile acid maltase deficiency. J Pediatr.
2000;137:283–285
14. Ausems MG, Verbiest J, Hermans MP, et al. Frequency of glycogen
storage disease type II in The Netherlands: implications for diagnosis
and genetic counselling. Eur J Hum Genet. 1999;7:713–716
15. Martiniuk F, Chen A, Mack A, et al. Carrier frequency for glycogen
storage disease type II in New York and estimates of affected individ-
uals born with the disease. Am J Med Genet. 1998;79:69–72
16. Van der Ploeg AT, Van der Kraaij AM, Willemsen R, et al. Rat heart
perfusion as model system for enzyme replacement therapy in glycog-
enosis type II. Pediatr Res. 1990;28:344–347
17. Van der Ploeg AT, Kroos MA, Willemsen R, Brons NH, Reuser AJ. In-
travenous administration of phosphorylated acid alpha-glucosidase
leads to uptake of enzyme in heart and skeletal muscle of mice. J Clin
Invest. 1991;87:513–518
18. Bijvoet AG, Kroos MA, Pieper FR, et al. Recombinant human acid
alpha-glucosidase: high level production in mouse milk, biochemical
characteristics, correction of enzyme deficiency in GSDII KO mice. Hum
Mol Genet. 1998;7:1815–1824
19. Bijvoet AG, Van Hirtum H, Kroos MA, et al. Human acid alpha-
glucosidase from rabbit milk has therapeutic effect in mice with glyco-
gen storage disease type II. Hum Mol Genet. 1999;8:2145–2153
20. De Duve C, Wattiaux R. Functions of lysosomes. Annu Rev Physiol.
1966;28:435–492
21. Hoefsloot LH, Hoogeveen-Westerveld M, Kroos MA, Van Beeumen J,
Reuser AJ, Oostra BA. Primary structure and processing of lysosomal
alpha-glucosidase: homology with the intestinal sucrase-isomaltase
complex. EMBO J. 1988;7:1697–1704
22. Martiniuk F, Mehler M, Tzall S, Meredith G, Hirschhorn R. Sequence of
the cDNA and 5-flanking region for human acid alpha-glucosidase,
detection of an intron in the 5 untranslated leader sequence, definition
of 18-bp polymorphisms, and differences with previous cDNA and
amino acid sequences. DNA Cell Biol. 1990;9:85–94
23. Hoefsloot LH, Hoogeveen-Westerveld M, Reuser AJ, Oostra BA. Char-
acterization of the human lysosomal alpha-glucosidase gene. Biochem J.
1990;272:493–497
24. Fuller M, Van der Ploeg A, Reuser AJ, Anson DS, Hopwood JJ. Isolation
and characterisation of a recombinant, precursor form of lysosomal acid
alpha-glucosidase. Eur J Biochem. 1995;234:903–909
25. Bijvoet AG, Kroos MA, Pieper FR, et al. Expression of cDNA-encoded
human acid alpha-glucosidase in milk of transgenic mice. Biochim Bio-
phys Acta. 1996;1308:93–96
26. Reuser AJ, Koster JF, Hoogeveen A, Galjaard H. Biochemical, immuno-
logical, and cell genetic studies in glycogenosis type II. Am J Hum Genet.
1978;30:132–143
27. Hermans MM, Kroos MA, Smeitink JA, van der Ploeg AT, Kleijer WJ,
Reuser AJ. Glycogen storage disease type II: genetic and biochemical
analysis of novel mutations in infantile patients from Turkish ancestry.
Hum Mutat. 1998;11:209–215
28. Reuser AJ, Kroos M, Oude Elferink RP, Tager JM. Defects in synthesis,
phosphorylation, and maturation of acid alpha-glucosidase in glycog-
enosis type II. J Biol Chem. 1985;260:8336–8341
29. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding
quantitation in M-mode echocardiography: results of a survey of echo-
cardiographic measurements. Circulation. 1978;58:1072–1083
30. Devereux RB, Casale PN, Kligfield P, et al. Performance of primary and
derived M-mode echocardiographic measurements for detection of left
ventricular hypertrophy in necropsied subjects and in patients with
systemic hypertension, mitral regurgitation and dilated cardiomyopa-
thy. Am J Cardiol. 1986;57:1388–1393
31. Piper MC, Darrah J. Motor Assessment of the Developing Infant. Philadel-
phia, PA: WB Saunders Company; 1994
32. Bayley N. Bayley Scales of Infant Development. 2nd ed. San Antonio, TX:
Harcourt Brace & Company; 1993
33. Van Hove JL, Yang HW, Wu JY, Brady RO, Chen YT. High-level
production of recombinant human lysosomal acid alpha-glucosidase in
Chinese hamster ovary cells which targets to heart muscle and corrects
glycogen accumulation in fibroblasts from patients with Pompe disease.
Proc Natl Acad Sci U S A. 1996;93:65–70
34. Hermans MM, De Graaff E, Kroos MA, et al. The effect of a single base
pair deletion (delta T525) and a C1634T missense mutation (pro545leu)
on the expression of lysosomal alpha-glucosidase in patients with gly-
cogen storage disease type II. Hum Mol Genet. 1994;3:2213–2218
e456 ENZYME THERAPY FOR POMPE DISEASE
35. Winkel LPF, Kamphoven JHJ, Van den Hout JMP, et al. Morphological
changes in muscle tissue of patients with infantile Pompe’s disease
receiving enzyme replacement therapy. Muscle Nerve. 2003;27:743–751
36. Vogel M, Staller W, Buhlmeyer K. Left ventricular myocardial mass
determined by cross-sectional echocardiography in normal newborns,
infants and children. Pediatr Cardiol. 1991;12:143–149
37. Wisselaar HA, Kroos MA, Hermans MM, Van Beeumen J, Reuser AJ.
Structural and functional changes of lysosomal acid alpha-glucosidase
during intracellular transport and maturation. J Biol Chem. 1993;268:
2223–2231
38. Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid
alpha-glucosidase enzyme therapy for infantile glycogen storage dis-
ease type II: results of a phase I/II clinical trial. Genet Med. 2001;3:
132–138
39. Eng C, Guffon N, Wilcox W, et al. Safety and efficacy of recombinant
human alpha-galactosidase a replacement therapy in Fabry’s disease.
N Engl J Med. 2001;345:9–16
40. Eng CM, Banikazemi M, Gordon RE, et al. A phase 1/2 clinical trial of
enzyme replacement in Fabry disease: pharmacokinetic, substrate clear-
ance, and safety studies. Am J Hum Genet. 2001;68:711–722
41. Grabowski GA, Leslie N, Wenstrup R. Enzyme therapy for Gaucher
disease: the first 5 years. Blood Rev. 1998;12:115–133
42. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in
mucopolysaccharidosis I. N Engl J Med. 2001;344:182–188
43. Schiffmann R, Kopp JB, Austin HA, et al. Enzyme replacement therapy
in Fabry disease. A randomized controlled trial. JAMA. 2001;285:2743–2749
44. Winkel LPF, Van den Hout JMP, Kamphoven JHJ, et al. Preliminary
findings in patients with juvenile Pompe’s disease treated with recom-
binant human alpha-glucosidase from rabbit milk. Am J Hum Genet.
2001;S96:674
45. Schiffmann R, Murray GJ, Treco D, et al. Infusion of alpha-galactosidase
A reduces tissue globotriaosylceramide storage in patients with Fabry
disease. Proc Natl Acad Sci U S A. 2000;97:365–370
46. Sands MS, Vogler CA, Ohlemiller KK, et al. Biodistribution, kinetics,
and efficacy of highly phosphorylated and non-phosphorylated beta-
glucuronidase in the murine model of mucopolysaccharidosis VII. J Biol
Chem. 2001;276:43160–43165
47. Raben N, Jatkar T, Lee A, et al. Glycogen stored in skeletal but not in
cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly
resistant to transgene-encoded human enzyme. Mol Ther. 2002;6:
601–608
http://www.pediatrics.org/cgi/content/full/113/5/e448 e457
